The thromboprotective effect of bortezomib is dependent on the transcription factor Kruppel-like factor 2 (KLF2)

Blood

Volumn 123, Issue 24, 2014, Pages 3828-3831

  Nayak, Lalitha ^a,b   Shi, Hong ^b   Atkins, G Brandon ^b   Lin, Zhiyong ^b   Schmaier, Alvin H ^a   Jain, Mukesh K ^b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CONVULXIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBRINOGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; KRUPPEL LIKE FACTOR 2; KRUPPEL LIKE FACTOR 4; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE ACTIVATED RECEPTOR 1; THROMBIN; THROMBOMODULIN; THROMBOPLASTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTITHROMBOTIC EFFECT; ARTICLE; BLEEDING TIME; CAROTID ARTERY THROMBOSIS; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; GENE DELETION; GENE OVEREXPRESSION; HEMATOPOIETIC CELL; LEUKOCYTE COUNT; MOUSE; MYELOMA CELL; NONHUMAN; PERINATAL PERIOD; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBIN TIME; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOSIS PREVENTION; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; BORONIC ACIDS; CAROTID ARTERY THROMBOSIS; CELLS, CULTURED; CORONARY OCCLUSION; CYTOPROTECTION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PYRAZINES; WHOLE BLOOD COAGULATION TIME;

EID: 84902578847     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-01-547448     Document Type: Article

References (25)

1. Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol. 2009;27(29):4839-4847.
2. Kristinsson SY, Pfeiffer RM, Björkholm M, et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood. 2010;115(24):4991-4998.
3. Bennett CL, Angelotta C, Yarnold PR, et al. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA. 2006;296(21):2558-2560. (Pubitemid 44903859)
4. Jagannath S, Durie BG, Wolf JL, et al. Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma. Br J Haematol. 2009;146(6):619-626.
5. Palumbo A, Gay F, Bringhen S, et al. Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. Ann Oncol. 2008;19(6):1160-1165. (Pubitemid 351796343)
6. Ostrowska JK, Wojtukiewicz MZ, Chabielska E, Buczko W, Ostrowska H. Proteasome inhibitor prevents experimental arterial thrombosis in renovascular hypertensive rats. Thromb Haemost. 2004;92(1):171-177. (Pubitemid 39010880)
7. Avcu F, Ural AU, Cetin T, Nevruz O. Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro. Thromb Res. 2008;121(4):567-571. (Pubitemid 351174280)
8. Zangari M, Guerrero J, Cavallo F, Prasad HK, Esseltine D, Fink L. Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma. Haematologica. 2008;93(6):953-954. (Pubitemid 351821742)
9. Shen Y, Zhou X, Wang Z, et al. Coagulation profiles and thromboembolic events of bortezomib plus thalidomide and dexamethasone therapy in newly diagnosed multiple myeloma. Leuk Res. 2011;35(2):147-151.
10. Dekker RJ, Boon RA, Rondaij MG, et al. KLF2 provokes a gene expression pattern that establishes functional quiescent differentiation of the endothelium. Blood. 2006;107(11):4354-4363. (Pubitemid 43801361)
11. McConnell BB, Yang VW. Mammalian Krüppellike factors in health and diseases. Physiol Rev. 2010;90(4):1337-1381.
12. Kuo CT, Veselits ML, Leiden JM. LKLF: A transcriptional regulator of single-positive T cell quiescence and survival. Science. 1997;277(5334):1986- 1990. (Pubitemid 27449139)
13. Das H, Kumar A, Lin Z, et al. Kruppel-like factor 2 (KLF2) regulates proinflammatory activation of monocytes. Proc Natl Acad Sci U S A. 2006;103(17):6653-6658.
14. SenBanerjee S, Lin Z, Atkins GB, et al. KLF2 Is a novel transcriptional regulator of endothelial proinflammatory activation. J Exp Med. 2004;199(10):1305-1315. (Pubitemid 38685723)
15. Lin Z, Kumar A, SenBanerjee S, et al. Kruppel-like factor 2 (KLF2) regulates endothelial thrombotic function. Circ Res. 2005;96(5):e48-e57.
16. Lin Z, Hamik A, Jain R, Kumar A, Jain MK. Kruppel-like factor 2 inhibits protease activated receptor-1 expression and thrombin-mediated endothelial activation. Arterioscler Thromb Vasc Biol. 2006;26(5):1185-1189. (Pubitemid 43732131)
17. Mahabeleshwar GH, Kawanami D, Sharma N, et al. The myeloid transcription factor KLF2 regulates the host response to polymicrobial infection and endotoxic shock. Immunity. 2011;34(5):715-728.
18. Nayak L, Goduni L, Takami Y, et al. Kruppel-like factor 2 is a transcriptional regulator of chronic and acute inflammation. Am J Pathol. 2013;182(5):1696-1704.
19. Hiroi T, Deming CB, Zhao H, et al. Proteasome inhibitors enhance endothelial thrombomodulin expression via induction of Krüppel-like transcription factors. Arterioscler Thromb Vasc Biol. 2009;29(10):1587-1593.
20. Shi H, Sheng B, Zhang F, et al. Kruppel-like factor 2 protects against ischemic stroke by regulating endothelial blood brain barrier function. Am J Physiol Heart Circ Physiol. 2013;304(6):H796-H805.
21. Nieman MT, Warnock M, Hasan AA, et al. The preparation and characterization of novel peptide antagonists to thrombin and factor VIIa and activation of protease-activated receptor 1. J Pharmacol Exp Ther. 2004;311(2):492-501. (Pubitemid 39391533)
22. Seizer P, Gawaz M, May AE. Platelet-monocyte interactions-a dangerous liaison linking thrombosis, inflammation and atherosclerosis. Curr Med Chem. 2008;15(20):1976-1980.
23. Zhang L, Zhang ZG, Liu X, et al. Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator. Thromb Haemost. 2006;95(1):166-173.
24. Zhang L, Zhang ZG, Buller B, et al. Combination treatment with VELCADE and low-dose tissue plasminogen activator provides potent neuroprotection in aged rats after embolic focal ischemia. Stroke. 2010;41(5):1001-1007.
25. Zhou G, Hamik A, Nayak L, et al. Endothelial Kruppel-like factor 4 protects against atherothrombosis in mice. J Clin Invest. 2012;122(12):4727- 4731. Prepublished on 2012/11/20 as.